Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
147 studies found for:    "Expanded Access" [STUDY-TYPES] | Open Studies
Show Display Options
RSS Create an RSS feed from your search for:
"Expanded Access" [STUDY-TYPES] | Open Studies
Need help? See RSS Feeds
Choose a feed type:
Show studies that were first received in the last 14 daysShow studies that were first received in the last 14 days
Show studies added or modified in the last 14 daysShow studies that were added or modified in the last 14 days
Rank Status Study
1 Available cliniMACs HUD for T Cell Depletion
Condition: x Linked Combined Immunodeficiency
Intervention: Device: CliniMACs
2 Available Rivaroxaban in Mechanical Valves: RIMV Study
Condition: Thromboembolism
Intervention: Drug: Rivaroxaban
3 Available A Phase I Study of DM-CHOC-PEN in Pediatric and Adolescent Subjects With Advanced Cancers
Condition: Document Safety for DM-CHOC-PEN in Pediatric and Adolescent Subjects With Advanced Cancer
Intervention: Drug: 4-Demethyl-4-cholesteryloxycarbonylpenclomedine
4 Available Early Patient Access Treatment Use Protocol CA204-220
Condition: Multiple Myeloma
Interventions: Drug: Elotuzumab;   Drug: Lenalidomide;   Drug: Dexamethasone
5 Available Compassionate Use of SOM230 for Hyperinsulinemic/Hypoglycemia
Condition: Congenital Hyperinsulinism
Intervention: Drug: Pasireotide
6 Available C11 Sodium Acetate PET/CT Imaging of PCa
Condition: Prostate Cancer
Intervention: Drug: Carbon-11 Sodium Acetate
7 Available Open-label Evaluation of Polymyxin B Hemoperfusion for Septic Shock
Conditions: Septic Shock;   Endotoxemia
Intervention: Device: TORAYMYXIN PMX-20R
8 Available Study of Allogeneic EBV-CTLs in EBV-Associated Lymphomas and Lymphoproliferative Disorders
Conditions: Epstein-Barr Virus-Associated Lymphoproliferative Disorder;   Epstein-Barr Virus Lymphoma;   Epstein-Barr Virus-Related Post-Transplant Lymphoproliferative Disorder
Intervention: Biological: Epstein-Barr Virus Cytotoxic T Lymphoctyes (EBV-CTLs)
9 Available Expanded Access Program for Ocrelizumab in Participants With Primary Progressive Multiple Sclerosis
Condition: Multiple Sclerosis
Intervention: Drug: Ocrelizumab
10 Available Expanded Access Program to Provide Abemaciclib (LY2835219) for the Treatment of Metastatic Breast Cancer
Condition: Metastatic Breast Cancer
Intervention: Drug: Abemaciclib
11 Available An Expanded Access Study of Brigatinib for Patients With ALK-positive Advanced Non-Small Cell Lung Cancer
Conditions: Non-small Cell Lung Cancer;   Lung Cancer;   Advanced Malignancies;   Carcinoma
Intervention: Drug: Brigatinib
12 Available Intravenous Fish Oils in the Treatment of Parenteral Nutrition Liver Injury
Conditions: Cholestasis;   Total Parenteral Nutrition-induced Cholestasis
Intervention: Drug: Omegaven
13 Available Compassionate Use of Omegaven
Condition: Cholestasis
Intervention: Dietary Supplement: Omegaven
14 Available Clinical Use of a Magnetic Anal Sphincter Augmentation Device, Trade Name FENIX
Condition: Fecal Incontinence
Intervention: Device: magnetic anal sphincter augmentation for fecal incontinence
15 Available Extended Treatment Access Study of MT-3724 for Subjects With Relapsed Non-Hodgkin's B-Cell Lymphoma
Condition: Non-Hodgkin's B-cell Lymphoma
Intervention: Drug: MT-3724
16 Available Expanded Access Protocol for Therapeutic Use of 177Lu-DOTA0-Tyr3-Octreotate in Patients With Inoperable, Somatostatin Receptor Positive, Midgut Carcinoid Tumors, Progressive Under Somatostatin Analogue Therapy
Condition: Midgut Carcinoid Tumor
Intervention: Drug: 177Lu-DOTA0-Tyr3-Octreotate
17 Available Compassionate Use of MitoGel in Upper Tract Urothelial Carcinoma
Condition: Urothelial Carcinoma Ureteral Location
Intervention: Drug: MitoGel
18 Available Low-profile Visualized Intraluminal Support -HUD
Condition: Giant Wide Necked Aneurysms
Intervention: Device: Low Profile Visualized Intraluminal Support Device
19 Available Expanded Access Protocol Using HBOC-201
Condition: Anemia
Intervention: Biological: HBOC-201
20 Available Early Patient Access Single Named Patient Program for the Use of Ulocuplumab for the Treatment of Multiple Myeloma
Conditions: Multiple Myeloma in Relapse;   Multiple Myeloma
Interventions: Drug: Ulocuplumab;   Drug: Lenalidomide;   Drug: Bortezomib;   Drug: Dexamethasone

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years